Recent advances in molecular genetics have enabled assessments of the associations among genetic variants (e.g., single-nucleotide polymorphisms) and susceptibility for complex diseases, including psychiatric disorders. Specifically, genome-wide association studies (GWAS), meta-analyses of the GWAS summary statistics, and mega-analyses (which use raw data, not summary statistics) of GWAS have provided revolutionary results and have identified numerous susceptibility genes or single-nucleotide polymorphisms. By using several tens of thousands of subjects, >40 genes have been identified as being associated with susceptibility for bipolar disorder so far. The purpose of this systematic review was to summarize the recent findings of bipolar disorder GWAS and discuss their clinical implications.
B
IPOLAR DISORDER (BD) IS a severe psychiatric disorder characterized by mood swings (depressive and manic phases) that can strongly influence patients' and families' quality of life. On the basis of the manic symptoms or durations, BD is divided into two main subtypes: bipolar I disorder with manic episodes and bipolar II disorder with hypomanic episodes (Note: Schizoaffective disorder is sometimes included in the BD category in clinical research, including genetic studies.)
The lifetime prevalence is not rare and has been reported as~1% worldwide 1 (with a much smaller prevalence of 0.2% in Japan 2 ); therefore, the economic burden associated with this disorder is huge. Nevertheless, the pathogenesis of BD remains unknown; several hypotheses have been proposed, the most famous one being the monoamine hypothesis, but these hypotheses do not fully explain all of the causes of BD. 3, 4 However, many epidemiologic studies have suggested that genetic factors have a key role in developing BD, and the heritability of BD is estimated to be approximately 0.8, 3 although environmental factors are also critical. 5 On the basis of these findings, genetic linkage and association studies have been conducted since the 1980s. In the current decade, owing to the surprising improvement in genotyping methods for genetic variants, a revolutionary new method, the genome-wide association study (GWAS), has been the main method used to assess associations among genetic variants (i.e., single nucleotide polymorphisms [SNP] ) and BD (not just for BD, but for all of the complex diseases, including psychiatric disorders). The main advantages of GWAS are: (i) we do not set candidate genes a priori, thus, 'unknown' genes with low prior probability can be identified as susceptibility genes for BD; and (ii) many subjects can be analyzed in one GWAS because of the low cost per sample, therefore susceptibility SNP with small effect sizes are detectable. There are some disadvantages of the use of GWAS, however. For example, a stringent significance level is required; usually, P-values < 5 × 10 −8 are set for a type I error (i.e., false positive) rate. This level seems quite low, but empirically, SNP less than this threshold are well replicated, which implies that type I errors are well controlled. From a different viewpoint, this means that the associations of many SNP had type II errors (i.e., false negative) because of their small effect size, but future meta-analyses of the GWAS summary statistics or mega-analyses, which use the raw genotype data (not just summary statistics), will be able to increase the sample size to avoid type II errors. There are other disadvantages involving technical details, such as controlling population stratification, but these are not within the scope of this review. 6 More recently, whole-exome sequencing (WES) or whole-genome sequencing (WGS) technologies have become established, and using these methods, several studies have been reported in prestigious journals. These findings are also outside the scope of this review. However, there is a good review available that summarizes recent findings of the studies using these new technologies. 7 In the present review, we present the results of GWAS for BD and provide a brief summary of the susceptibility genes for BD and discuss their clinical implications.
SEARCH STRATEGY
We performed a GWAS Catalog search (https:// www.ebi.ac.uk/gwas/) on 4 September 2017. 'Bipolar disorder' was used as a search term, and 85 studies were identified. We extracted the purer results by filtering 'catalog traits' as 'bipolar disorder (n = 24)' and 'bipolar I disorder (n = 2)'; thus, 26 studies were included. We further filtered to extract SNP with genome-wide significance (5 × 10
) and detected 39 variants as candidate SNP. In addition, we searched bioRxiv (http://www. biorxiv.org/) manually and found the latest results reported by Stahl et al. 34 That study identified 30 SNP with genome-wide significance associated with BD.
SUMMARY OF GWAS FINDINGS
Among the 27 studies (Table 1) , 12 studies (69 SNP) showed genome-wide significance ( Table 2 ). Ten of the 12 studies comprising a European-based sample were analyzed, and two studies targeted East Asian/European subjects in the discovery phases (Table 1) .
Before the 'Psychiatric Genomics Consortium (2011, Nat. Genet.)' era Before the Psychiatric Genomics Consortium (PGC) paper was published in 2011, 21 sample sizes were not very large. Although several genes have been reported as susceptibility genes with genome-wide significance, most of these were not well replicated. Among them, the oldest and most replicated genes are ankyrin 3 (ANK3: http://omim.org/entry/ 600465) and calcium voltage-gated channel subunit alpha1 C (CACNA1C: http://omim.org/entry/ 114205). The functions of these genes have been well documented in other papers, 35, 36 and it is of interest that the variants of ANK3 and CACNA1C influence white-matter integrity and brain volume, 37 which indicates that the genetic variants are associated with brain function as intermediate phenotypes.
A hallmark study conducted by PGC (2011, Nat. Genet.)
The study conducted by the PGC 21 is recognized as a hallmark study because the discovery GWAS (7481 European ancestry cases, 9250 European ancestry controls) as well as replication analysis (4496 European ancestry cases, 42 422 European ancestry controls) provided an extremely large sample size compared with those reported previously. Prior to the PGC study, most studies had been conducted in a single or small collaborative research group except for two studies (Ferreira et In this study, 21 the BD working group conducted a discovery GWAS, and for the top hits (P < 5 × 10 −5 ), they conducted a replication analysis using large independent samples. Consequently, they detected two susceptibility genes for BD: One is an SNP in CACNA1C and another is an SNP in ODZ4 (known as TENM4). It is of note that the effect size of the susceptibility SNP was not large: 1.14 for CACNA1C and 0.88 (=1/0.88 = 1.14) for ODZ4. However, this is not surprising, because the 38 had a magnitude similar to the effect size for BD.
The authors pointed out two other important findings.
21 First, they reported that the effect size of the top SNP selected by the discovery GWAS tended to have the same direction in the replication phase: 31 out of 34 'candidate' SNP showed the same direction (sign test P = 3.8 × 10
−7
). This finding indicates that the 'candidate' SNP are likely to become genuine signals and the genetic risk of BD remains undetectable under their sample size because of the extremely small effect size. Further, this finding implies that BD is a polygenic disorder, similar to SCZ, in which numerous SNP with small effect sizes contribute to development of BD. Second, they observed a shared genetic effect of the susceptibility SNP of BD with those of SCZ. The authors performed a joint analysis by merging association results based on SCZ and found that two SNP (in CACNA1C and NEK4/ITIH1,3,4) revealed a stronger association than that of the BD GWAS analysis alone. These results support the shared genetic risk between BD and SCZ mentioned later.
After the 'PGC (2011, Nat. Genet.)' era After the PGC study, 21 the sample size of the discovery GWAS became larger (Table 1) . However, the number of novel susceptibility genes for BD was limited. (Note: PGC results are open and, thus, are publicly available for download at http://www.med. unc.edu/pgc/results-and-downloads/downloads; therefore, after the PGC results, the researchers used them in their discovery GWAS or replication results. 28, 32, 33 ) The largest 'PGC-independent' study was conducted by Hou et al. 31 and used approximately 35 000 subjects (7647 European ancestry cases, 27 303 European ancestry controls). They detected a couple of novel susceptibility genes (POU3F2/ MIR2113, DDN, and ERBB2; Table 2 ), but most of the SNP with genome-wide significance have been reported previously. Among the significant genes, the most promising are TRANK1 and MAD1L1 because the PGC results showed that these genes were associated with P-values just below genomewide significance. Therefore, these genes were replicated by using independent samples, which makes them promising candidate genes. However, there is still a functional connection between TRANK1 (and other significant genes), and BD remains uncertain.
Another interesting and novel susceptibility gene is Fatty acid desaturase 1/2/3 (FADS1/2/3), which was detected by our research group (advanced COSMO). 33 It is also noteworthy that this study used a non-European sample and was the largest in the East Asian population. FADS genes encode key enzymes to regulate the desaturation of n-3/n-6 polyunsaturated fatty acids. Interestingly, a number of genetic variants in the FADS1/2/3 region are highly associated with the plasma levels of n-3/n-6 polyunsaturated fatty acids [39] [40] [41] and other general lipids (i.e., HDL/LDL/TG/T-cholesterol), 42 and the susceptibility SNP for BD are the quantitative trait loci SNP with such blood lipid traits. [39] [40] [41] [42] Therefore, these are the first results with clear functional relevance connected to BD, which indicates that the lipid abnormality may be associated with the © 2017 The Authors Psychiatry and Clinical Neurosciences © 2017 Japanese Society of Psychiatry and Neurology pathophysiology of BD. This view is supported by traditional epidemiologic surveys in which the prevalence of hyperlipidemia or metabolic syndrome in BD was found to be more common than that in the general population. [43] [44] [45] Furthermore, to avoid the medication effect (second-generation antipsychotics have a high risk for dyslipidemia or type II diabetes), studies with small sample sizes have shown increased prevalences of metabolic syndrome in first-degree relatives of psychosis subjects (including those with BD) 46 and in drug-naïve patients with BD. 39 In any case, further study is needed to establish a causal relationship of lipid abnormality with BD.
Most recent study by the 'updated' PGC (Stahl et al., 2017) Recently, the largest study led by the PGC was posted on bioRxiv (http://www.biorxiv.org/content/ early/2017/08/08/173062.1). 34 The sample size was striking and comprised approximately 30 000 BD cases (20 352 discovery GWAS and 9412 replicates) and~169 000 controls (31 358 discovery GWAS and 137 760 replicates). In this study, they reported 30 loci as susceptibility genes for BD, and 20 loci were novel; the most significant association was observed at the SNP in TRANK1 (rs9834970, P = 5.7 × 10 −12 , OR = 0.93), which had been reported previously (Table 2) . Additionally, several interesting regions have been listed, although the functional relevance remains unclear. Therefore, it is difficult to pinpoint the 'genuine' susceptibility genes solely on the basis of these results. Transethnic replication analysis is reasonable for this purpose and in this aspect, it is stressed that the SNP near FADS genes were associated with BD in the updated PGC data, which indicated that the trans-population effect exists in the FADS region as a risk for BD between European and Asian 33 populations.
In addition, the PGC discussed several important findings: (i) the risks of BD I, II, and schizoaffective disorder (SA) are genetically shared, except for BD II-SA; (ii) there are significant genetic overlaps between BD and other psychiatric disorders or neurological phenotypes (mentioned below); and (iii) several pathways were candidates for BD susceptibility (neuron number, endocannabinoid signaling, and several ion-channel transports).
Genetic overlap of the BD susceptibility SNP with other psychiatric disorders
In the 19th century, Emil Kraepelin proposed the classification of an amorphous group of madness disorders into two dimensions (i.e., the Kraepelin dichotomy): dementia praecox (i.e., SCZ) and manic-depressive illness (i.e., BD). Basically, current diagnostic criteria, such as that of the DSM and the ICD follow this concept. However, a growing number of epidemiologic and genetic studies have been reported (in this regard, good reviews that present criticisms of the 'Kraepelin dichotomy' have been published). [47] [48] [49] Briefly, epidemiologic surveys have shown increased prevalences of SCZ and BD in the first-degree relatives of the probands of SCZ or BD. 50 Furthermore, GWAS results supported this observation on the basis of an SNP association analysis: The top SNP for BD susceptibility have been found to be associated with SCZ (and vice versa), as mentioned above 21 and have been reported by others. [51] [52] [53] Additionally, analyses using a polygenic model, such as the polygenic risk profile score (RPS) analysis and genetic correlation analysis, also support the shared genetic risk between the two disorders. Initial findings were reported in 2009 by the International Schizophrenia Consortium, 54 in which a higher polygenic score calculated from many SNP defined as 'risks' for SCZ was observed in BD relative to that in controls. The PGC Cross Disorder Group comprehensively analyzed and replicated the shared genetic risk between BD and SCZ/major depressive disorder (MDD). 55 In a recent report by Stahl et al. 34 the authors analyzed the relationship among BD subtypes (BD I, II, and SA) and SCZ/MDD. Interestingly, they observed that: (i) the polygenic score based on SCZ risk was higher in BD I than in BD II; whereas (ii) scores based on MDD risk were higher in BD II than in BD I. These results indicate that BD I-SCZ (and BD II-MDD) is closer than BD II-SCZ (and BD I-MDD). This is reasonable from a clinical viewpoint. (Note: The authors applied this analysis within BD samples as a simulation and found that the polygenic score based on a part of BD was higher in the remaining BD patients than in the controls. This evidence was observed within BD patients in a Japanese population or across populations between Japanese and Europeans. 
CLINICAL IMPLICATIONS BASED ON GWAS FINDINGS
The most striking fact from the results of the BD GWAS is that the effect size of the susceptibility SNP is extremely small (e.g., odds ratio~1.2), and the magnitude was similar to that of SCZ 38 and MDD. 56, 57 Additionally, numerous numbers of SNP and probably their combination or geneenvironment interaction 58 will contribute to development of BD. Therefore, current definitive 'susceptibility SNP' are not sufficient as diagnostic tools. Even if the polygenic score based on RPS analysis is used as a predictor for developing BD, the discriminative power will be limited (i.e., the score cannot distinguish the phenotype between cases [BD] and controls). 59 However, it is of note that RPS analyses could potentially identify clinical subtypes or treatment responses in psychiatric patients, including those with BD; for example, early-onset MDD had a higher polygenic score based on the BD risk. This finding suggests that clinicians should consider that patients with early-onset MDD may be at risk for development of BD, and it is reasonable in a clinical sense. 60 Recently, direct-to-consumer (DTC) genetic testing has gained momentum, and many people have used these tests to examine their genetic personal risks (in most of the cases, DTC companies use GWAS results for risk prediction), although DTC genetic tests for medical use are prohibited in many countries. However, a leading society, the International Society of Psychiatric Genetics, does not recommend 'DTC genetic testing for medical purposes in patients with psychiatric illness or their families' (https:// ispg.net/genetic-testing-statement/, however, in Japan, apolipoprotein E for Alzheimer's disease is available from some DTC companies). Therefore, to interpret the DTC results, the important facts that should be kept in mind are that: (i) most of the common risk SNP for many complex diseases (identified as risks so far) and even polygenic scores for psychiatric disorders are not perfect predictors for use as diagnostic tools; whereas (ii) the genetic variants with high effect sizes will be useful for evaluation of a person's risk for a certain disease or pharmacogenomic trait. In the future, DTC may use WES/WGS results. In that case, the DTC companies and the 'real' clinical settings, including psychiatrists, must establish a 'good environment' to use genetic information for determining psychiatric risk or for best selection of therapeutic agents as precision medicines. [61] [62] [63] Again, we stress that common genetic variants do not have a large impact on the diagnosis for BD. Consequently, we have to ask what is the purpose of conducting genetic studies? The answer is that identification of genes that influence the relations between molecular function and disease may contribute to development of novel therapeutic agents and provide hints for the development of precision medicines. 64, 65 Thus, it is important to continue research that identifies novel susceptibility genes for BD and other complex disorders, probably by increasing sample sizes and by using other molecular genetic techniques, such as next-generation sequencing.
CONCLUSIONS
A growing number of GWAS findings have been reported, and among them, those from the PGC BD Group study have had a great impact on BD genetics. 21 To date, a smaller number of BD susceptibility genes have been detected than those for SCZ, so the PGC have been using larger sample sizes. Therefore, more BD genes will be identified in the near future. Similar to analyses of other diseases, those for BD that use larger sample sizes will be able to detect more susceptibility genes, which will help fill in missing information regarding heritability and to provide novel evidence for development of new drugs and precision medicines.
